Advanced search
Publication Cover
Leukemia & Lymphoma Volume 22, 1996 - Issue 1-2
Submit an article Journal homepage
13
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Toxicity Profile of the Investigational New Biotherapeutic Agent, B43 (Anti-CD 19)-Pokeweed Antiviral Protein Immunotoxin

Roland Gunther University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Lisa M. Chelstrom University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Heather R. Wendorf University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Elizabeth A. Schneider University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Kristi Covalciuc University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Bradley Johnson University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Dina Clementson University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
James D. Irvin University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
,
Dorothea E. Myers University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
&
Fatih M. Uckun University of Minnesota Biotherapy Program and the Centralized Immunotoxin Resource Laboratory of the Childrens Cancer Group, Roseville, Minnesota, Southwest Texas State University, San Marcos, TexasUSA
 show all
Pages 61-70 | Received 10 Aug 1995, Published online: 01 Jul 2009

References

  • Waddick K.G., Gunther R., Chelstrom L.M., Chandan-Langlie M., Myers D.E., Irvin J.D., Turner N., Uckun F.M. In vitro and in vivo anti-leukemic activity of B43 (anti-CD19)-poke-weed antiviral protein immunotoxin against radiation resistant human pre-B acute lymphoblastic leukemia cells. Blood 1995; 86: 4228–4233
  • Uckun F.M., Manivel C., Arthur D., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Gunther R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–2214
  • Uckun F.M., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Manivel C., Irvin J.D., Myers D.E., Gunther R. Effective immunochemotherapy of CALLA + Cμ + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–3129
  • Gunther R., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Uckun F.M. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia 1993; 7: 298–309
  • Jansen B., Kersey J.H., Jaszcz W.B., Gunther R., Nguyen D.P., Chelstrom L.M., Tuel-Ahlgren L., Uckun F.M. Effective immunochemotherapy of human t(4;l 1) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-D 19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1993; 7: 290–297
  • Myers D.E., Uckun F.M. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia. Leuk. Lymph. 1995; 18: 119–122
  • Myers D.E., Yanishevski Y., Masson E., Irvin J.D., Evans W.E., Uckun F.M. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Leuk. Lymph. 1995; 18: 93–102
  • Gunther R., Chelstrom L.M., Tuel-Ahlgren L., Simon J., Myers D.E., Uckun F.M. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin. Blood 1995; 85: 2537–2545
  • Uckun F.M., Myers D.E., Irvin J.D., Kuebelbeck V.M., Finnegan D., Chelstrom L.M., Houston L.L. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity, and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin. Leuk. Lymph. 1993; 9: 459–476
  • Myers D.E., Irvin J.D., Smith R.S., Kuebelbeck V.M., Uckun F.M. Production of a pokeweed antiviral protein (PAP)-con-taining immunotoxin, B43-PAP, directed against the CD19 human B-lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. M. 1991; 136: 221–238
  • Uckun F.M., Reaman G.H. Immunotoxins for treatment of leukemia and lymphoma. Leuk. Lymph. 1995; 18: 195–201
  • Uckun F.M. Immunotoxins for the treatment of leukemia (Review). Brit. J. Haematol. 1993; 85: 435–438

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.